RxDoctor Payments Data

Kan Huang, MD

Hematology & Oncology · Rolla, MONPI 1598095622

Payments from drug & device makers

$8,256in general payments, 2019–2025

Across 324 payments — averaging $25.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novartis$695
  • Johnson & Johnson$544
  • Merck$422
  • Incyte Corporation$400
  • Genentech USA, Inc.$340
  • plus $4K from 49 others

What the payments were for

  • Consulting fees$1,38817%
  • Travel & lodging$5046%
  • Food & beverage$6,21175%
  • Education$1532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,256 in reported general payments places this provider in the 60th percentile of 211 hematology & oncology providers in Missouri.

See all hematology & oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$112,361
Medicare patients
223
Services billed
867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WeliregBelzutifan11$328,371
OrserduElacestrant Hcl12$283,981
PomalystPomalidomide11$247,280
InlytaAxitinib11$230,519
BosulifBosutinib18$203,537
IbrancePalbociclib13$192,853
EliquisApixaban62$46,862
Abiraterone Acetate23$46,399
XareltoRivaroxaban21$12,915
Everolimus12$11,561
Ondansetron Hcl50$4,644
Prochlorperazine Maleate43$1,438
Anastrozole97$944
Oxycodone Hcl42$928
Dexamethasone60$887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerInlyta, Bosulif, Ibrance, Eliquis$318$673,772104 claims
MerckWelireg$422$328,37111 claims
Stemline Therapeutics Inc.Orserdu$78$283,98112 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$243$247,28011 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$15$46,39923 claims
Johnson & JohnsonXarelto$544$12,91521 claims
Lilly USA, LLCOlanzapine$99$10556 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 211 hematology & oncology providers in Missouri.

Other hematology & oncology in Rolla

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →